Who Owns Akebia Company?

Akebia Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Akebia Therapeutics?

Understanding a company's ownership structure is crucial for investors and stakeholders alike. Akebia Therapeutics, a biopharmaceutical firm focusing on kidney disease treatments, recently underwent a significant transformation with its public offering in March 2025. This shift has reshaped the landscape of Akebia SWOT Analysis, making it essential to understand who controls its destiny.

This analysis dives deep into Akebia ownership, exploring the evolution from its founders, Joseph Gardner and Robert Shalwitz, to the current mix of institutional investors and public shareholders. We'll examine the impact of key players and how the company's share structure influences its strategic direction and financial performance. Discover the answers to questions like "Who are Akebia's major investors?" and "How to buy Akebia stock?" as we uncover the intricate details of Akebia Therapeutics' ownership dynamics.

In 2007, Joseph Gardner and Robert Shalwitz, M.D., established Akebia Therapeutics. Dr. Shalwitz, a co-founder, brought extensive industry experience in pharmaceutical development to the table. The company's initial focus was on addressing unmet medical needs in ischemia and vascular diseases, later expanding into kidney disease.

Early financial backing was crucial for Akebia Therapeutics. The company secured substantial funding in its initial years to support its research and development efforts. These early investments were critical in shaping the company's trajectory.

The founders' vision for Akebia Therapeutics centered on innovative treatments. While specific details on initial equity splits aren't publicly available, their combined expertise and strategic direction laid the groundwork for the company's future.

Series A Funding

On July 28, 2009, Akebia secured $25 million in a Series A funding round. Lead investors included Venture Investors and Novartis Venture Fund.

Series B Funding

A Series B funding round followed on April 26, 2011, raising an additional $22 million. This round included participation from the same lead investors and others.

Early Investors

Early investors played a vital role in shaping Akebia's initial direction. Triathlon Medical Venture Partners, Orchard Venture Partners, Kearny Venture Partners, Athenian Venture Partners, and AgeChem Venture Partners were also involved.

Initial Focus

Akebia's initial focus was on ischemia and vascular diseases. The company later expanded its research to include kidney disease treatments.

Founders' Vision

The founders' vision was to address unmet medical needs. This vision guided the company's early research and development efforts.

Financial Foundation

The early funding rounds provided a solid financial foundation. These investments were crucial for Akebia's growth.

The early financial support and strategic direction set the stage for Akebia Therapeutics' development. For more details on the company's financial structure, you can explore the Revenue Streams & Business Model of Akebia.

Akebia SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Akebia Therapeutics has seen significant changes since its inception, especially after becoming a publicly traded entity. The company's shares are listed on The Nasdaq Capital Market under the symbol 'AKBA.' As of March 10, 2025, there were 236,231,057 shares of Akebia's Common Stock outstanding. This evolution is crucial for understanding who owns Akebia and how the company is governed.

A key event that impacted the ownership structure was a public offering of 25,000,000 shares of common stock at $2.00 per share, priced on March 19, 2025, and expected to close on March 21, 2025. This offering aimed to raise gross proceeds of $50.0 million, with net proceeds estimated at approximately $46.5 million. The company also granted underwriters a 30-day option to purchase up to an additional 3,750,000 shares. This offering significantly impacted the company's financial position, increasing cash and cash equivalents to approximately $113.4 million by March 31, 2025, compared to $51.9 million at December 31, 2024. These changes reflect the ongoing dynamics of Akebia ownership and its strategic financial maneuvers.

Major institutional investors hold a considerable portion of Akebia's stock. As of May 2025, institutional investors held 36.93% of the company, with mutual funds increasing their holdings to 25.36%. Key institutional shareholders as of March 31, 2025, include BlackRock, Inc. (15,332,163 shares), Vanguard Group Inc (12,685,803 shares), and State Street Corp (6,805,807 shares). The influence of these major shareholders shapes the company's strategic direction. For more insights, you can explore the Competitors Landscape of Akebia.

Ownership and Investment

Understanding Akebia's ownership structure is vital for investors and stakeholders. This includes tracking institutional and insider holdings, as well as changes resulting from public offerings.

• Institutional investors play a significant role.
• Public offerings can dramatically alter the financial landscape.
• Insider ownership provides insights into company confidence.
• Shareholder interests directly influence company decisions.

Akebia PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current Board of Directors of Akebia Therapeutics plays a vital role in the company's governance. As of June 10, 2025, John P. Butler and Myles Wolf, M.D., M.M.Sc., were re-elected as Class II directors, with their terms extending until the 2028 annual meeting of stockholders. The leadership team also includes key figures like Meredith Bowman (SVP, Chief People Officer), Steven K. Burke, M.D. (SVP, Research & Development and Chief Medical Officer), Kimberly Garko (SVP, Chief Technical Officer), Nicholas Grund (SVP, Chief Commercial Officer), Erik Ostrowski (SVP, Chief Financial Officer and Chief Business Officer), and Carolyn Rucci (SVP, Legal, General Counsel, Secretary). Director Leanne M. Zumwalt's expertise in the U.S. dialysis market is also notable.

Understanding the structure of Akebia ownership is crucial for investors. This structure is influenced by the board's decisions and shareholder voting power. For further insight into the company's background, you can review the Brief History of Akebia.

The voting structure at Akebia Therapeutics is generally one-share-one-vote, giving each outstanding share of common stock the right to vote. The company's 2023 Stock Incentive Plan was amended on June 10, 2025, increasing the shares available for issuance by 18,900,000 shares. This decision, along with director elections and an advisory vote on executive compensation, was part of the Annual Meeting agenda. There have been no recent proxy battles or significant activist investor campaigns publicly reported.

Key Takeaways on Akebia's Governance

The Board of Directors is key in making decisions about Akebia Therapeutics. Understanding the voting structure and the roles of the directors is essential for anyone looking at Akebia stock.

• The board includes experienced professionals.
• Shareholders have voting rights based on the number of shares they own.
• Recent amendments to the stock incentive plan show the company's focus on equity.
• There are no recent proxy fights or activist campaigns.

Akebia Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Akebia Therapeutics has seen significant shifts in its ownership structure and financial health. In March 2025, the company completed a public offering, raising $50 million in gross proceeds. This capital injection increased its cash reserves to approximately $113.4 million by March 31, 2025, a substantial increase from $51.9 million at the end of 2024. These financial maneuvers have positioned the company to pursue its strategic objectives.

Industry trends for Akebia ownership indicate a growing presence of institutional investors. As of May 2025, institutional investors held 36.93% of the company's shares, with mutual funds increasing their holdings to 25.36%. Key institutional holders include BlackRock Inc., Vanguard Group Inc, and State Street Corp. Insider holdings remained consistent at 4.57% during the same period. This shift suggests increasing confidence from larger financial entities in Akebia stock and its future prospects.

In the first quarter of 2025, Akebia Therapeutics reported a net income of $6.1 million, a significant improvement from a net loss of $18.0 million in Q1 2024. This turnaround was driven by a rise in net product revenues, including the initial sales of Vafseo, which generated $12.0 million. The company anticipates that its current cash resources and operational cash flow will be sufficient to fund its operating plan for at least two years. Furthermore, Akebia plans to initiate the VALOR Phase 3 trial for vadadustat in non-dialysis CKD patients in the second half of 2025, demonstrating its commitment to expanding its product pipeline and addressing unmet medical needs. For more detailed information about the company, you can read more about it here.

Akebia Stock Performance

The company's stock performance reflects the changes in ownership and financial results. Tracking the Akebia stock price and market capitalization provides insights into investor sentiment. The recent public offering and positive financial results may influence future stock performance.

Institutional Ownership

Institutional investors play a crucial role in Akebia's ownership structure. Understanding the holdings of major institutional investors, such as BlackRock and Vanguard, offers insights into their confidence in the company's long-term prospects. Increased institutional ownership often indicates positive sentiment.

Insider Ownership

Insider ownership, the shares held by company executives and board members, provides insights into the alignment of interests. Consistent insider ownership, like the 4.57% observed in May 2025, suggests confidence in the company's strategy. Tracking changes in insider holdings can reveal important signals.

Future Outlook

The company's strategic initiatives, including the VALOR Phase 3 trial, and its financial performance will be key drivers of future Akebia shareholders value. Monitoring Akebia's ability to achieve profitability and successfully commercialize its products is crucial for investors.

Akebia Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs